An MM Expert Shares New Developments
Hear Dr Sikander Ailawadhi, Hematologist-Oncologist, discuss multiple myeloma, including unmet need and targets under investigation.
DISEASE STATE
Multiple myeloma (MM) originates in the bone marrow and secondary lymphoid organs, where B cells undergo differentiation before transforming into plasma cells.1 Mutations occur when B cells differentiate and lead to the formation of malignant plasma cells that produce an abnormal amount of nonfunctional antibodies (M-protein).1,2
Learn about MM, including changes to the treatment landscape.
Multiple myeloma prevalence3,4
Multiple myeloma is the third most common hematologic cancer. In 2023, it is estimated that there will be 35,730 new cases and 12,590 deaths in the U.S.
Multiple myeloma is most frequently diagnosed among patients aged 65-74 years.
Median age
at diagnosis is
69 years
Higher incidences in Black and male patients
